Bridge Medical is a global evidence and outcomes research consulting firm. Since 2011 we have supported many leading pharmaceutical companies to deliver evidence of value to regulators, payers, clinicians and patients across all major therapeutic areas.
Together with client colleagues in medical affairs, health outcomes, drug development and epidemiology, our shared goal is to deliver patient access to innovative treatments based on the transparent provision of robust evidence.
Where strategy meets methodology. Integrated development, medical and health outcomes planning to meet the complex needs of multiple stakeholders.
A full spectrum service from systematic literature reviews with meta-analysis for external submissions, through to pragmatic literature reviews for internal decision making.
Transparent reporting of disease and subgroup prevalence & incidence. Development of long term disease burden models.
Designing study concepts through to full protocol writing. Clinical trials and real world studies. From Phase II to Phase IV.
Crystallising research questions. Mapping optimal sources of data. Descriptive and predictive analytics of clinical trial data and real world data.
Scientific platform documents and clear evidence based communication to strategic stakeholders including regulators, payers, physicians and patients.
|Network meta-analysis [NMA] is now a widely accepted approach for comparative efficacy research. As well as providing a brief introduction to NMA, here we summarise some the main criticisms of NMAs submitted by manufacturers to Health Technology Assessment bodies. We also list the key appraisal tools used to assess the quality of NMAs.|
|The Adaptive Pathway initiative is an EMA project to examine the possibility of incremental drug licensing in order to allow those most in need to access new medicines as soon as possible. Central to the concept is the use of Real World data in the licensing process. Here we examine the status of the Adaptive Pathway initiative using publically available information, with a specific focus on the RWD component.|
|In the context of adaptive licensing and real world evidence there is increasing focus on the potential value of pragmatic trials. Here we describe the "pragmatic continumm" and we also interview Dr David Leather of GSK about the Salford Lung Study- a landmark pre-license pragmatic trial.|
|Adaptive trial designs have proliferated in the past few years with methods gaining acceptance with academia and regulatory agencies. But are these study designs only relevant to exploratory development, or are they relevant to confirmatory development as well?|
|As greater focus shifts to real world data, what techniques exist to handle bias and confounding? Here we briefly describe the concept of instrumental variables.|
|As greater focus shifts to real world data what techniques exist to handle bias and confounding – here we briefly describe the concept of propensity score matching.|
|Is Goal Attainment Scaling the ultimate measure of functioning ? – In the new edition of Evidence Notes we examine the key properties of this instrument designed to be a bespoke measure of functioning in clinical research.|
|All pivotal trials submitted to regulators need to have blinded treatment allocation, right ? Not always. Read our short article in Issue 2 of Evidence Notes on PROBE study designs to find out more about open label blinded endpoint studies.|
|Balancing internal and external validity in a single study is always a challenge. The cohort multiple randomised control trial (cmRCT) approach has been suggested as a way of achieving a balance. Here is our short review of the method and it's applicability to pharmaceutical research.|
We are an experienced team of physicians, epidemiologists, outcomes researchers and statisticians who are passionate about solving evidence challenges from a range of perspectives. As well as having deep-seated scientific and clinical knowledge, our people are commercially aware, creative and solution-focused in their approach.
At Bridge Medical, our mission is to become the world's most respected evidence and outcomes-focused consultancy. To achieve this goal, we will continue to collaborate with forward-thinking clients who believe that delivering a robust, compelling and evolving evidence base to external stakeholders is the main route to achieving patient benefits and securing business goals.
The success of the Bridge Medical approach has led to a rapidly growing client base and increasing demand for our services. To help us fulfil our increasing work obligations and allow us to continue to innovate, we are always looking for talented physicians and scientists—for whom integrity in clinical research is paramount —to join our team.
We are actively recruiting across all levels of our organisation, and are particularly interested to hear from candidates with >5 years experience in clinical or outcomes research within the pharmaceutical sector.
If you wish to be considered for our in-depth technical interview process, please submit a current CV and a 1-page cover letter explaining your relevant experience and interest in joining Bridge Medical.